PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

Core Insights - Pulse Biosciences, Inc. (PLSE) has initiated a research collaboration with The University of Texas MD Anderson Cancer Center to test its nPulse technology, Vybrance, for treating malignant thyroid tumors, with FDA approval for human trials [1][5] Clinical Trial Details - The clinical trial is set to begin in early 2026, enrolling 30 patients across two sites to assess the safety of the nPulse Vybrance Percutaneous Electrode System for treating papillary thyroid microcarcinoma, a prevalent thyroid cancer in the U.S. [2] Pre-Clinical Studies - MD Anderson researchers are conducting pre-clinical studies on nsPFA energy as a potential treatment for anaplastic thyroid carcinoma, which has a five-year survival rate of less than 5% [3] Stock Performance - Following the announcement, PLSE shares increased by 1.4% during the last closing, but have declined 21.4% year-to-date, contrasting with a 3% rally in the industry and an 18.6% rise in the S&P 500 [4] Strategic Importance - The partnership with MD Anderson and FDA's IDE approval enhances PLSE's competitive position in the soft-tissue ablation market for thyroid cancer treatment, adding credibility to its nsPFA technology [5][9] Technology Overview - The nPulse Vybrance Percutaneous Electrode System utilizes a small needle electrode to deliver precise, non-thermal ablation of cancer tissue while protecting surrounding healthy tissues, positioning it as a potential breakthrough treatment for both benign and malignant thyroid tumors [10] Future Growth Potential - The collaboration with MD Anderson provides a solid clinical foundation for PLSE to build evidence and expand its technology into new medical areas, indicating long-term growth potential in the oncology market [11]